AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Calmodulin-lysine N-methyltransferase

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q7Z624

UPID:

CMKMT_HUMAN

Alternative names:

-

Alternative UPACC:

Q7Z624; Q4ZG15; Q53SS6; Q8N6P5; Q9H5G8

Background:

Calmodulin-lysine N-methyltransferase, encoded by the gene with accession number Q7Z624, plays a crucial role in post-translational modifications by catalyzing the trimethylation of 'Lys-116' in calmodulin. This specific enzymatic activity is pivotal for the regulation of calcium signaling pathways, which are fundamental for cellular processes.

Therapeutic significance:

The protein is implicated in Hypotonia-cystinuria syndrome, a condition marked by generalized hypotonia, nephrolithiasis, and growth hormone deficiency. Understanding the role of Calmodulin-lysine N-methyltransferase could open doors to potential therapeutic strategies for this syndrome and related metabolic disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.